L K Seymour

Summary

Affiliation: Queen's University
Country: Canada

Publications

  1. ncbi request reprint The design of clinical trials for new molecularly targeted compounds: progress and new initiatives
    Lesley Seymour
    National Cancer Institute of Canada Clinical Trials Group, Queens University, 18 Barrie Street, Kingston, Ontario, K7L 3N6, Canada
    Curr Pharm Des 8:2279-84. 2002
  2. doi request reprint Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated end point?
    Penelope Bradbury
    From the NCIC Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
    Cancer J 15:354-60. 2009
  3. doi request reprint Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies
    Lesley K Seymour
    NCIC Clinical Trials Group, Kingston, Canada
    Eur J Cancer 49:1808-14. 2013
  4. pmc The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee
    Lesley Seymour
    NCIC Clinical Trials Group, Kingston, Ontario, Canada
    Clin Cancer Res 16:1764-9. 2010
  5. ncbi request reprint A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity
    L Seymour
    Investigational New Drug Program, National Cancer Institute of Canada Clinical Trial Group, Queens University, Kingston, Ontario
    Cancer Chemother Pharmacol 47:2-10. 2001
  6. ncbi request reprint Epidermal growth factor receptor inhibitors: an update on their development as cancer therapeutics
    Lesley Seymour
    National Cancer Institute of Canada Clinical Trials Group, Queens University, Kingston, Ontario, K7L3N6, Canada
    Curr Opin Investig Drugs 4:658-66. 2003
  7. ncbi request reprint Epidermal growth factor receptor as a target: recent developments in the search for effective new anti-cancer agents
    L K Seymour
    Investigational New Drug Program, National Cancer Institute of Canada Clinical Trials Group, Queens University, Kingston, Ontario, Canada
    Curr Drug Targets 2:117-33. 2001
  8. ncbi request reprint Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models
    Theodora Voskoglou-Nomikos
    National Cancer Institute of Canada Clinical Trials Group, Cancer Clinical Trials Division, Cancer Research Institute, Queen s University, 10 Stuart Street, Kingston, Ontario, K7L 3N6 Canada
    Clin Cancer Res 9:4227-39. 2003
  9. doi request reprint Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer
    Penelope A Bradbury
    NCIC Clinical Trials Group, Kingston, ON, Canada
    J Natl Cancer Inst 102:298-306. 2010
  10. ncbi request reprint Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies
    Eric X Chen
    National Cancer Institute of Canada, Clinical Trials Group, Kingston, Ontario, Canada
    Invest New Drugs 23:455-65. 2005

Collaborators

Detail Information

Publications33

  1. ncbi request reprint The design of clinical trials for new molecularly targeted compounds: progress and new initiatives
    Lesley Seymour
    National Cancer Institute of Canada Clinical Trials Group, Queens University, 18 Barrie Street, Kingston, Ontario, K7L 3N6, Canada
    Curr Pharm Des 8:2279-84. 2002
    ..Progress in this area of early trial design are reviewed...
  2. doi request reprint Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated end point?
    Penelope Bradbury
    From the NCIC Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
    Cancer J 15:354-60. 2009
    ..We review here the historical and current information regarding objective tumor response...
  3. doi request reprint Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies
    Lesley K Seymour
    NCIC Clinical Trials Group, Kingston, Canada
    Eur J Cancer 49:1808-14. 2013
    ....
  4. pmc The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee
    Lesley Seymour
    NCIC Clinical Trials Group, Kingston, Ontario, Canada
    Clin Cancer Res 16:1764-9. 2010
    ..The design of any clinical trial should always be carefully evaluated and justified based on characteristic specific to the situation...
  5. ncbi request reprint A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity
    L Seymour
    Investigational New Drug Program, National Cancer Institute of Canada Clinical Trial Group, Queens University, Kingston, Ontario
    Cancer Chemother Pharmacol 47:2-10. 2001
    ..To determine if this was a general phenomenon, we undertook a review of the results of a large group of phase I trials of cytotoxic agents...
  6. ncbi request reprint Epidermal growth factor receptor inhibitors: an update on their development as cancer therapeutics
    Lesley Seymour
    National Cancer Institute of Canada Clinical Trials Group, Queens University, Kingston, Ontario, K7L3N6, Canada
    Curr Opin Investig Drugs 4:658-66. 2003
    ..Early data suggest a number of potential roles for these agents in the modulation of resistance and in combination with other inhibitors of signal transduction...
  7. ncbi request reprint Epidermal growth factor receptor as a target: recent developments in the search for effective new anti-cancer agents
    L K Seymour
    Investigational New Drug Program, National Cancer Institute of Canada Clinical Trials Group, Queens University, Kingston, Ontario, Canada
    Curr Drug Targets 2:117-33. 2001
    ..Although these new compounds offer exciting opportunities, they bring with them real challenges in terms of the selection of appropriate trial designs as well as surrogate endpoints...
  8. ncbi request reprint Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models
    Theodora Voskoglou-Nomikos
    National Cancer Institute of Canada Clinical Trials Group, Cancer Clinical Trials Division, Cancer Research Institute, Queen s University, 10 Stuart Street, Kingston, Ontario, K7L 3N6 Canada
    Clin Cancer Res 9:4227-39. 2003
    ..We looked at the value of three preclinical cancer models, the in vitro human cell line, the human xenograft, and the murine allograft, to examine whether they are reliable in predicting clinical utility...
  9. doi request reprint Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer
    Penelope A Bradbury
    NCIC Clinical Trials Group, Kingston, ON, Canada
    J Natl Cancer Inst 102:298-306. 2010
    ..We undertook an economic analysis of erlotinib treatment in this trial and explored different molecular and clinical predictors of outcome to determine the cost-effectiveness of treating various populations with erlotinib...
  10. ncbi request reprint Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies
    Eric X Chen
    National Cancer Institute of Canada, Clinical Trials Group, Kingston, Ontario, Canada
    Invest New Drugs 23:455-65. 2005
    ..Bay 38-3441 was well tolerated in this study with granulocytopenia as the main hematologic toxicity. This study showed that glycoconjugation is a feasible delivery technique for camptothecin...
  11. pmc Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer
    Chang Qi Zhu
    University Health Network, Ontario Cancer Institute and Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 28:4417-24. 2010
    ..10 trial demonstrated benefit from adjuvant cisplatin/vinorelbine (ACT) in early-stage non-small-cell lung cancer (NSCLC). We hypothesized that expression profiling may identify stage-independent subgroups who might benefit from ACT...
  12. doi request reprint Alternate endpoints for screening phase II studies
    Neesha Dhani
    Princess Margaret Hospital, Toronto, Ontario, Canada
    Clin Cancer Res 15:1873-82. 2009
    ..Alternate endpoints, although promising, require additional evaluation and prospective validation before their use as a primary endpoint for phase II trials...
  13. ncbi request reprint Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
    Andrea Bezjak
    Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 24:3831-7. 2006
    ..This report describes the quality of life (QOL) findings of a randomized placebo controlled study of erlotinib, an epidermal growth factor receptor inhibitor, in patients with non-small-cell lung cancer (NSCLC)...
  14. ncbi request reprint Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval
    John Goffin
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
    Clin Cancer Res 11:5928-34. 2005
    ..Given that spontaneous regressions are observed in melanoma and renal cell carcinoma, this study assessed whether tumor responses, particularly in these two tumor types, predict for future regulatory drug approval...
  15. ncbi request reprint Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer
    Srikala S Sridhar
    Division of Medical Oncology, Department of Medicine of the University Health Network, Princess Margaret Hospital and the University of Toronto, Canada
    Lancet Oncol 4:397-406. 2003
    ....
  16. ncbi request reprint Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials
    Massimo Di Maio
    National Cancer Institute, Naples, Italy
    Lancet Oncol 6:669-77. 2005
    ..We aimed to assess whether haematological toxic effects could be a biological measure of drug activity and a marker of efficacy...
  17. ncbi request reprint A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients
    Manijeh Daneshmand
    Ottawa Regional Cancer Centre, Ottawa, Ontario, K1H 1C4 Canada
    Clin Cancer Res 9:2457-64. 2003
    ..Immunohistochemistry for EGFR, activated EGFR, phosphorylated Akt, phosphorylated ERK, p27(Kip1), and beta-catenin was also performed...
  18. ncbi request reprint A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer
    Mary J Mackenzie
    Hamilton Regional Cancer Centre, 699 Concession St, Hamilton, ON, Canada L8V 5C2
    Invest New Drugs 23:165-70. 2005
    ....
  19. ncbi request reprint Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours
    Lyly H Le
    Princess Margaret Hospital, 610 University Ave, Toronto, ON, M5G 2M9, Canada
    Cancer Chemother Pharmacol 56:154-60. 2005
    ..This phase I study was designed to determine the maximum tolerated dose (MTD) of zosuquidar in combination with vinorelbine. The effects of zosuquidar on vinorelbine pharmacokinetics were also examined...
  20. ncbi request reprint Erlotinib in previously treated non-small-cell lung cancer
    Frances A Shepherd
    Department of Medical Oncology, University Health Network, Princess Margaret Hospital Site, University of Toronto, Canada
    N Engl J Med 353:123-32. 2005
    ....
  21. doi request reprint Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer
    Martin Fruh
    Department of Medical Oncology, Princess Margaret Hospital, Toronto
    J Clin Oncol 26:3573-81. 2008
    ..This pooled analysis was undertaken to assess the efficacy and toxicity of adjuvant cisplatin-based chemotherapy in elderly patients with non-small-cell lung cancer (NSCLC)...
  22. doi request reprint Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
    Chang Qi Zhu
    FRCPC, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario, Canada M5G 2M9
    J Clin Oncol 26:4268-75. 2008
    ..To evaluate the effect of KRAS and epidermal growth factor receptor (EGFR) genotype on the response to erlotinib treatment in the BR.21, placebo-controlled trial...
  23. doi request reprint A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21
    Marie Florescu
    Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Hospital Site and University of Toronto, Toronto, Canada
    J Thorac Oncol 3:590-8. 2008
    ..BR.21 demonstrated significant survival benefit for non-small cell lung cancer patients receiving erlotinib compared with placebo. We undertook to characterize, by exploratory subset analysis, patients less likely to benefit from erlotinib...
  24. doi request reprint Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group
    Jean Pierre Pignon
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    J Clin Oncol 26:3552-9. 2008
    ..The aim of the Lung Adjuvant Cisplatin Evaluation was to identify treatment options associated with a higher benefit or groups of patients who particularly benefit from postoperative chemotherapy...
  25. doi request reprint Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
    Paul Wheatley-Price
    Department of Medical Oncology, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario, M5G 2M9 Canada
    J Clin Oncol 26:2350-7. 2008
    ..21 established erlotinib as a standard of care in patients with non-small-cell lung cancer (NSCLC) after failure of first- or second-line chemotherapy. The current study analyzes the influence of age on outcomes in BR.21...
  26. doi request reprint A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)
    Jennifer J Knox
    Princess Margaret Hospital University Health Network, University of Toronto, Toronto, ON, Canada M5G 2M9
    Invest New Drugs 26:265-72. 2008
    ..Among these patients with preserved hepatic function and good performance status, SB-715992 was generally well tolerated. However, no conclusive evidence of benefit was seen with SB-715992 monotherapy in HCC...
  27. ncbi request reprint A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial
    Christopher W Lee
    BC Cancer Agency Fraser Valley Centre, 13750 96th Avenue, Surrey, BC, Canada V3V 1Z2
    Invest New Drugs 26:249-55. 2008
    ..Although KSP expression appears to be common in melanoma, KSP may not be a suitable target for its treatment...
  28. ncbi request reprint Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib
    Gary M Clark
    OSI Pharmaceuticals, Inc, Boulder, CO 80301, USA
    J Thorac Oncol 1:837-46. 2006
    ..Because not all patients benefit from erlotinib, epidermal growth factor receptor (EGFR) protein expression may provide a basis for selecting patients for treatment with this EGFR inhibitor...
  29. ncbi request reprint Erlotinib in lung cancer - molecular and clinical predictors of outcome
    Ming Sound Tsao
    University Health Network, Princess Margaret Hospital Site, and the Ontario Cancer Institute, University of Toronto, Canada
    N Engl J Med 353:133-44. 2005
    ....
  30. ncbi request reprint Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21
    Gary M Clark
    OSI Pharmaceuticals, Inc, Boulder, CO 80301, USA
    Clin Lung Cancer 7:389-94. 2006
    ..21, a randomized double-blind study of 731 patients with advanced-stage non-small-cell lung cancer...
  31. ncbi request reprint Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days
    Karl Belanger
    Centre Hospitalier de l Universite de Montreal CHUM, Hopital Notre Dame, 1560 Sherbrooke Street East, Montreal, Quebec, Canada H2L 4M1 corrected
    J Clin Oncol 20:2567-74. 2002
    ..We conducted a phase I study of troxacitabine given as a 30-minute infusion once every 21 days...
  32. ncbi request reprint A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130
    Karen A Gelmon
    British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada, V5Z 4E6
    Invest New Drugs 23:445-53. 2005
    ..This phase I trial was conducted to determine the maximum tolerated dose, recommended phase II dose, pharmacokinetic properties and toxicities of this agent...
  33. ncbi request reprint Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Orga
    Frances A Shepherd
    National Cancer Institute of Canada Clinical Trials Group
    J Clin Oncol 20:4434-9. 2002
    ..This trial was undertaken to determine whether adjuvant treatment with the metalloproteinase inhibitor marimastat could prolong survival in responding patients with SCLC after chemotherapy...